BRPI0821408A2 - Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação - Google Patents

Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação

Info

Publication number
BRPI0821408A2
BRPI0821408A2 BRPI0821408-5A BRPI0821408A BRPI0821408A2 BR PI0821408 A2 BRPI0821408 A2 BR PI0821408A2 BR PI0821408 A BRPI0821408 A BR PI0821408A BR PI0821408 A2 BRPI0821408 A2 BR PI0821408A2
Authority
BR
Brazil
Prior art keywords
long
dosage regimen
acting injectable
regimen associated
injectable paliperidone
Prior art date
Application number
BRPI0821408-5A
Other languages
English (en)
Portuguese (pt)
Inventor
An Margriet Cornelia Vermeulen
Alfons Jeanne Wouters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40428256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821408(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0821408A2 publication Critical patent/BRPI0821408A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/08—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
    • H01L31/10—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by potential barriers, e.g. phototransistors
    • H01L31/101—Devices sensitive to infrared, visible or ultraviolet radiation
    • H01L31/102—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier
    • H01L31/109—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier the potential barrier being of the PN heterojunction type

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Power Engineering (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Computer Hardware Design (AREA)
  • Dermatology (AREA)
  • Electromagnetism (AREA)
  • Manufacturing & Machinery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0821408-5A 2007-12-19 2008-12-17 Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação BRPI0821408A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1491807P 2007-12-19 2007-12-19
US12027608P 2008-12-05 2008-12-05
PCT/EP2008/067738 WO2009080651A1 (en) 2007-12-19 2008-12-17 Dosing regimen associated with long acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
BRPI0821408A2 true BRPI0821408A2 (pt) 2015-06-16

Family

ID=40428256

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821408-5A BRPI0821408A2 (pt) 2007-12-19 2008-12-17 Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação

Country Status (26)

Country Link
US (3) US9439906B2 (ko)
EP (2) EP3909585A1 (ko)
JP (1) JP5825786B2 (ko)
KR (3) KR102318070B1 (ko)
CN (2) CN105560176A (ko)
AU (2) AU2008340101B2 (ko)
BR (1) BRPI0821408A2 (ko)
CO (1) CO6300949A2 (ko)
CY (1) CY1124103T1 (ko)
DK (1) DK2234617T3 (ko)
EA (1) EA020697B1 (ko)
EC (1) ECSP10010289A (ko)
ES (1) ES2868353T3 (ko)
GT (1) GT201000182A (ko)
HK (1) HK1223850A1 (ko)
HR (1) HRP20210669T1 (ko)
HU (1) HUE053904T2 (ko)
IL (2) IL206448A (ko)
LT (1) LT2234617T (ko)
NI (1) NI201000105A (ko)
NZ (1) NZ586221A (ko)
PL (1) PL2234617T3 (ko)
PT (1) PT2234617T (ko)
RS (1) RS61765B1 (ko)
SI (1) SI2234617T1 (ko)
WO (1) WO2009080651A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5825786B2 (ja) 2007-12-19 2015-12-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US9522980B2 (en) 2010-05-06 2016-12-20 Johnson & Johnson Vision Care, Inc. Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
RU2627469C2 (ru) * 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
DK2529756T3 (da) 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US10073192B2 (en) 2012-05-25 2018-09-11 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
NZ748572A (en) 2012-09-19 2020-07-31 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
EP3185867B1 (en) 2014-08-25 2021-01-13 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
BR112017017608A2 (pt) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
EP3744326B1 (en) * 2015-04-07 2023-12-06 Janssen Pharmaceutica NV Dosing regimen for missed doses for long-acting injectable paliperidone esters
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CA3077224A1 (en) * 2017-10-27 2019-05-02 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110279659A (zh) * 2019-07-08 2019-09-27 华裕(无锡)制药有限公司 棕榈酸帕利哌酮制剂及其制备方法
GR1009869B (el) * 2019-07-12 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
KR20230116837A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
HUE065573T2 (hu) 2020-11-30 2024-06-28 Janssen Pharmaceutica Nv Elnyújtott felszabadulású paliperidon injektálható készítményeihez kapcsolódó adagolási rendek
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1491807A (en) 1922-06-20 1924-04-29 John P Mclinn Traveling bag
US1491809A (en) 1923-02-17 1924-04-29 Us Fireworks Mfg Company Inc Toy
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
KR100338776B1 (ko) * 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
CA2494825C (en) 2002-08-21 2009-02-17 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20060079846A1 (en) 2004-10-08 2006-04-13 Alton Williams Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
DE07811307T1 (de) 2006-08-14 2008-07-31 Teva Pharmaceutical Industries Ltd. Amorphe und Kristlline Formen von 9-Hydroxyrisperidon (Paliperidon)
WO2009025859A1 (en) 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
CA2700803A1 (en) 2007-10-09 2009-04-16 Rajendra Narayanrao Kankan Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
JP5825786B2 (ja) 2007-12-19 2015-12-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
US11114549B2 (en) 2017-11-29 2021-09-07 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor structure cutting process and structures formed thereby
US11450758B2 (en) 2020-06-12 2022-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. Gate structure of semiconductor device and method of forming same

Also Published As

Publication number Publication date
KR102318070B1 (ko) 2021-10-27
RS61765B1 (sr) 2021-05-31
GT201000182A (es) 2012-03-26
ECSP10010289A (es) 2010-07-30
CN105560176A (zh) 2016-05-11
EP2234617A1 (en) 2010-10-06
ES2868353T3 (es) 2021-10-21
US20090163519A1 (en) 2009-06-25
US20170128451A1 (en) 2017-05-11
US9439906B2 (en) 2016-09-13
PT2234617T (pt) 2021-05-18
US20180147210A1 (en) 2018-05-31
NI201000105A (es) 2011-03-17
CO6300949A2 (es) 2011-07-21
KR20170018489A (ko) 2017-02-17
CN101932327A (zh) 2010-12-29
PL2234617T3 (pl) 2021-11-08
SI2234617T1 (sl) 2021-07-30
NZ586221A (en) 2012-08-31
KR20100099292A (ko) 2010-09-10
HK1223850A1 (zh) 2017-08-11
JP2011506555A (ja) 2011-03-03
DK2234617T3 (da) 2021-05-25
HUE053904T2 (hu) 2021-07-28
EA020697B1 (ru) 2015-01-30
IL206448A0 (en) 2010-12-30
CY1124103T1 (el) 2022-05-27
JP5825786B2 (ja) 2015-12-02
AU2008340101A1 (en) 2009-07-02
AU2015200801B2 (en) 2016-12-15
LT2234617T (lt) 2021-05-25
KR102163196B1 (ko) 2020-10-12
KR20190049933A (ko) 2019-05-09
EP2234617B1 (en) 2021-03-31
EP3909585A1 (en) 2021-11-17
AU2008340101B2 (en) 2015-02-19
AU2015200801A1 (en) 2015-03-12
IL253468A0 (en) 2017-09-28
EA201070757A1 (ru) 2011-02-28
WO2009080651A1 (en) 2009-07-02
IL206448A (en) 2017-12-31
HRP20210669T1 (hr) 2021-10-29

Similar Documents

Publication Publication Date Title
BRPI0821408A2 (pt) Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
BR112012010195A2 (pt) regime de dosagem associado a ésteres de paliperidona injetável de longa ação
IL247079A0 (en) A rapidly dissolving pharmaceutical compound
SMT201600321B (it) Composizione iniettabile a rilascio graduale antipsicotica
ZA201304709B (en) A pharmaceutical dosage form
ZA201400404B (en) Offshore platform with outset columns
AP2011005979A0 (en) Pharmaceutical composition for a hepatitis C viralprotease inhibitor.
PL2445552T3 (pl) Przyrząd aplikacyjny z funkcją reaktywacji
ZA201401447B (en) A fast dissolving pharmaceutical composition
BRPI0913377A2 (pt) regime de dosagem
ZA201207839B (en) Pharmaceutical composition comprising a pyrimidineone derivative
DK2477931T3 (da) Vægtstangsarrangement til en gaffeltruck
ZA201304633B (en) A pharmaceutical composition
HK1181649A1 (en) A fast dissolving pharmaceutical composition
DE112010002595A5 (de) Anschlagschraube mit einem anschlagpufferteil
HK1149497A1 (en) A solid pharmaceutical formulation
BR112012003107A2 (pt) composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral
DK2316780T3 (da) Mast til et reolbetjeningsapparat
PT2588243E (pt) Bocal de receção de jato para um injetor de distribuição de pó mais injetor de distribuição
BRPI0818258A2 (pt) formulações injetáveis de longa ação
FR2936570B1 (fr) Propulseur a combustible nano-energetique
ZA201201003B (en) A pharmaceutical composition
IT1391951B1 (it) Dispositivo di raccordo a barriera perforabile
GB0803943D0 (en) A platform barrier arrangement
GB0813299D0 (en) Injectable medications

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL